Unique ID issued by UMIN | UMIN000011852 |
---|---|
Receipt number | R000013848 |
Scientific Title | Catheter Ablation of Right Atrial Ganglionated Plexi in Patients with Supraventricular Tachycardia and Atrial Fibrillation |
Date of disclosure of the study information | 2013/09/24 |
Last modified on | 2013/09/24 18:01:43 |
Catheter Ablation of Right Atrial Ganglionated Plexi in Patients with Supraventricular Tachycardia and Atrial Fibrillation
Catheter Ablation of Right Atrial Ganglionated Plexi in Patients with Supraventricular Tachycardia and Atrial Fibrillation
Catheter Ablation of Right Atrial Ganglionated Plexi in Patients with Supraventricular Tachycardia and Atrial Fibrillation
Catheter Ablation of Right Atrial Ganglionated Plexi in Patients with Supraventricular Tachycardia and Atrial Fibrillation
Japan |
Atrial fibrillation, Suprarventricular tachycardia, Atrial flutter, WPWsyndrome
Cardiology |
Others
NO
Research for the efficacy of the catheter ablation to atrial ganglionated plexi in atrial fibrillation patients with supraventricular tachycardia.
Efficacy
Confirmatory
Pragmatic
Not applicable
Recurrence of atrial fibrillation and supraventricular tachycardia
Cardiovascular events, Administration of antiarrhythmic drugs, Shocks in patients with implantable cardioverter difibrillators
Interventional
Parallel
Randomized
Individual
Single blind -participants are blinded
Active
NO
NO
Institution is not considered as adjustment factor.
NO
No need to know
2
Treatment
Maneuver |
Catheter ablation for right arterial ganglionated plexi in addition to ablation for WPW syndrome, superaventricular tachycardia or atrial flutter
Catheter ablation for right arterial ganglionated plexi
20 | years-old | <= |
Not applicable |
Male and Female
1)Patients who have a plan to be performed catheter ablation to WPW syndrome, atrial flutter, supraventricular tachycardia
2)Patients complicated with atrial fibrillation
3)more than or equal to 20 year old
4)Patients who consented to this clinical trial through the informed consent process in writing of the applicant.
1)A patient who did not consent to this clinical trial through the informed consent process in writing of the applicant.
2)The case in which the chief complaint is developed by atrial fibrillation.
3)Patients who participate in other clinical trials.
4)Patients who have a plan to be performed catheter ablation to left atrium.
5)Patients who underwent MAZE operation.
6)Atrial fibrillation responsible for the sympathetic nervous system. For example, induced by excise.
80
1st name | |
Middle name | |
Last name | Marehiko Ueda |
Chiba-university hospital
The department of cardiovascular medicine
1-8-1 Inohana Chuo-ku Chiba-city Chiba-prefecture
043-222-7171
zta10540@nifty.com
1st name | |
Middle name | |
Last name | Masayuki Ishimura |
Chiba-university hospital
The department of cardiovascular medicine
1-8-1 Inohana Chuo-ku Chiba-city Chiba-prefecture
090-3690-6511
marnet0826@yahoo.co.jp
The department of cardiovascular medicine, Chiba university hospital
The department of cardiovascular medicine, Chiba university hospital
Self funding
NO
2013 | Year | 09 | Month | 24 | Day |
Unpublished
Preinitiation
2013 | Year | 09 | Month | 23 | Day |
2013 | Year | 09 | Month | 27 | Day |
2013 | Year | 09 | Month | 24 | Day |
2013 | Year | 09 | Month | 24 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000013848